Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In Niger, epidemic meningococcal meningitis is primarily caused by Neisseria meningitidis (Nm) serogroup A. However, since 2002, Nm serogroup W135 has been considered to be a major threat that has not yet been realized, and an unprecedented incidence of Nm serogroup X (NmX) meningitis was observed in 2006. METHODS: Meningitis surveillance in Niger is performed on the basis of reporting of clinically suspected cases. Cerebrospinal fluid specimens are sent to the reference laboratory in Niamey, Niger. Culture, latex agglutination, and polymerase chain reaction are used whenever appropriate. Since 2004, after the addition of a polymerase chain reaction-based nonculture assay that was developed to genogroup isolates of NmX, polymerase chain reaction testing allows for the identification of Nm serogroup A, Nm serogroup B, Nm serogroup C, NmX, Nm serogroup Y, and Nm serogroup W135. RESULTS: From January to June 2006, a total of 4185 cases of meningitis were reported, and 2905 cerebrospinal fluid specimens were laboratory tested. NmX meningitis represented 51% of 1139 confirmed cases of meningococcal meningitis, but in southwestern Niger, it represented 90%. In the agglomeration of Niamey, the reported cumulative incidence of meningitis was 73 cases per 100,000 population and the cumulative incidence of confirmed NmX meningitis was 27.5 cases per 100,000 population (74.6 cases per 100,000 population in children aged 5-9 years). NmX isolates had the same phenotype (X : NT : P1.5), and all belonged to the same sequence type (ST-181) as the NmX isolates that were circulating in Niamey in the 1990s. Nm serogroup W135 represented only 2.1% of identified meningococci. CONCLUSIONS: This is, to our knowledge, the first report of such a high incidence of NmX meningitis, although an unusually high incidence of NmX meningitis was also observed in the 1990s in Niamey. The increasing incidence of NmX meningitis is worrisome, because no vaccine has been developed against this serogroup. Countries in the African meningitis belt must prepare to face this potential new challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A high incidence of serogroup X disease was recently reported for Niger, representing 51% of 1,139 confirmed cases of meningococcal meningitis in 2006 (36).”
From Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis (2010) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maiden, M. C. J., Bygraves, J. A., Feil, E., Morelli, G., Russell, J. E., Urwin, R., Zhang, Q., Zhou, J., Zurth, K., Caugant, D. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3140 · Cited by 3,833 · cited 1×
“A relevant selection of Nm isolates that had been collected during the meningitis epidemic season were sent to the World Health Organization’s Collaborating Centre for Reference and Research on Meningococci (Le Pharo, Marseilles, France) for serogroup confirmation, serotyping, and further determination, including mult…”
MethodBulletin of the World Health Organization
C., N. H. (1955) · The British Journal of Sociology · doi:10.2307/587237 · Cited by 3,601
mlstdbNet – distributed multi-locus sequence typing (MLST) databases
Jolley, K. A., Chan, M.-S., & Maiden, M. C. (2004) · BMC Bioinformatics · doi:10.1186/1471-2105-5-86 · Cited by 501 · cited 1×
“This publication made use of the Neisseria Multi Locus Sequence Typing website [26] developed by Keith Jolley and Man-Suen Chan and sited at the University of Oxford [29].”
MethodPCR for capsular typing of Haemophilus influenzae
Falla, T. J., Crook, D. W., Brophy, L. N., Maskell, D., Kroll, J. S., & Moxon, E. R. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.10.2382-2386.1994 · Cited by 413
Meningococcal meningitis in Africa
Greenwood, B. (1999) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(99)90106-2 · Cited by 358
Cerebrospinal meningitis in Africa.
Lapeyssonnie, L. (1963) · Europe PMC (PubMed Central) · Cited by 321
Taha, M.-K. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.2.855-857.2000 · Cited by 260 · cited 2×
“For genogrouping of Nm-positive specimens, a second PCR is performed to amplify the siaD gene for Nm serotypes B, C, Y, and W135, and the open reading frame 2 of the mynB gene for NmA [16].”
MethodSelf-citationEpidemiology of bacterial meningitis in Niamey, Niger, 1981-96.
Campagne, G., Schuchat, A., Djibo, S., Ousseini, A., Cissé, L., & Chippaux, J. (1999) · Europe PMC (PubMed Central) · Cited by 182
Self-citationGarcía, P., García, J., García, E., & López, R. (1986) · Gene · doi:10.1016/0378-1119(86)90215-5 · Cited by 168
Chatelet, I. P. D., Traore, Y., Gessner, B. D., Antignac, A., Naccro, B., Njanpop-Lafourcade, B.-M., Ouedraogo, M. S., Tiendrebeogo, S. R., Varon, E., & Taha, M. K. (2005) · Clinical Infectious Diseases · doi:10.1086/426436 · Cited by 158 · cited 6×
“In 2002, the first epidemic ever identified in Africa as being caused by Nm serogroup W135 occurred in Burkina Faso [9] [10], and the risk of a rapid spread of the epidemic within the meningitis belt was considered to be high.”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 10
- Koumare B, Bougoudogo F, Cisse M, Doumbia T, Keita MM. Bacte- riological aspects of purulent meningitis in Bamako district: a propos of 1541 bacterial strains collected from 1979 to 1991 [in French]. Bull Soc Pathol Exot 1993; 86:136-40.
- 1993, Bulletin de la Soci t de pathologie exotique (1990), 86, 136
- Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a se- rogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002; 185:618-26.
- Parent du Chatelet I, Traore Y, Gessner BD, et al. Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain re- action testing. Clin Infect Dis 2005; 40:17-25.
- World Health Organization. Meningococcal disease, serogroup W135, Burkina Faso: preliminary report, 2002. Wkly Epidemiol Rec 2002; 77: 152-5.
- World Health Organization (WHO). Enhanced surveillance of epi- demic meningococcal meningitis in Africa: a three-year experience. Wkly Epidemiol Rec 2005; 80:313-20.
- 2002, Weekly epidemiological record / Health Section of the Secretariat of the League of Nations, 77, 152
- 2005, Weekly epidemiological record / Health Section of the Secretariat of the League of Nations, 80, 313
- Multi Disease Surveillance Centre (MDSC). Epidemiological situation of week 22 to 26, 2006. MDSC Meningitis Weekly Bulletin. Ouaga- dougou: World Health Organization-Regional Office for Africa, 2006.
- Traore Y, Njanpop-Lafourcade BM, Adjogble KL, et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006; 43:817-22.
Cited by
Items 101–200 of 269
Sié, A., Pflüger, V., Coulibaly, B., Dangy, J., Kapaun, A., Junghanss, T., Pluschke, G., & Leimkugel, J. (2008) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2008.02056.x · Cited by 34
“…epidemics in the meningitis belt in the last 100 years, other serogroups such as C (Whittle et al. 1975), W135 (Taha et al. 2000; Fonkoua et al. 2002; Njanpop-Lafourcade et al. 2005) and X (Gagneux et al. 2002; Djibo et al. 2003; Boisier et al. 2007) have also caused outbreaks of considerable size.”
BackgroundXie, O., Bolgiano, B., Gao, F., Lockyer, K., Swann, C. J., Jones, C., Delrieu, I., Njanpop‐Lafourcade, B., Tamekloe, T. A., Pollard, A. J., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.032 · Cited by 33
“[1] Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Mainassara HB, et al.”
BackgroundCarbohydrate based meningococcal vaccines: past and present overview
Berti, F., Romano, M. R., Micoli, F., & Adamo, R. (2021) · Glycoconjugate Journal · doi:10.1007/s10719-021-09990-y · Cited by 31
Tall, H., Hugonnet, S., Donnen, P., Dramaix‐Wilmet, M., Kambou, J. L., Drabo, F., & Mueller, J. E. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-2 · Cited by 31
“Most episodes of epidemic meningitis occur in the African Meningitis Belt and have been caused by serogroup A of Neisseria meningitidis (Nm) [1], although serogroups W135 and X have been found to cause epidemics during the last decade [2-5].”
BackgroundResultSchoen, C. U., Joseph, B., Claus, H., Vogel, U. F., & Frosch, M. (2007) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2007.04.003 · Cited by 31
Bettinger, J. A., Deeks, S. L., Halperin, S. A., Tsang, R. S. W., & Scheifele, D. W. (2013) · Cited by 31
Assaf‐Casals, A., & Dbaibo, G. S. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1143157 · Cited by 30
“Serogroup X has recently shown epidemic potential in the sub-Saharan region.(5,12) In the Americas, the incidence of meningococcal disease is 0.”
BackgroundEvolving meningococcal immunization strategies
Sáfadi, M. A. P., Bettinger, J. A., Maturana, G. M., Enwere, G., & Borrow, R. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.979799 · Cited by 30
“6 cases per 100,000 population in children 5–9 years of age [100].”
BackgroundMeningococcal disease: The advances and challenges of meningococcal disease prevention
Yogev, R., & Tan, T. Q. (2011) · Human Vaccines · doi:10.4161/hv.7.8.16270 · Cited by 30
Rose, A., Mueller, J. E., Gerstl, S., Njanpop‐Lafourcade, B., Page, A., Nicolas, P., Traoré, R. O., Caugant, D. A., & Guerin, P. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011086 · Cited by 30
“Although most large meningitis epidemics in sub-Saharan Africa are still caused by Neisseria meningitidis serogroup A [1], recent meningococcal outbreaks caused by serogroups W135 [2,3] and X [4,5] underline the importance of serogroup-specific bacteriological surveillance and outbreak investigation.”
BackgroundSelf-citationNext generation rapid diagnostic tests for meningitis diagnosis
Feagins, A. R., Ronveaux, O., Taha, M., Caugant, D. A., Smith, V., Fernandez, K., Glennie, L., Fox, L. M., & Wang, X. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.08.049 · Cited by 30
Self-citationGala, R. P., D’Souza, M. J., & Zughaier, S. M. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.010 · Cited by 29
Neisseria meningitidisinfection: who, when and where?
Gianchecchi, E., Torelli, A., Piccini, G., Piccirella, S., & Montomoli, E. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1070096 · Cited by 28
Bårnes, G. K., Kristiansen, P. A., Beyene, D., Workalemahu, B., Fissiha, P., Merdekios, B., Bohlin, J., Préziosi, M., Aseffa, A., & Caugant, D. A. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1975-3 · Cited by 28
Kristiansen, P. A., Ba, A. K., Sanou, I., Ouédraogo, A., Ouédraogo, R., Sangaré, L., Diomandé, F. V. K., Kandolo, D., Thomas, J. D., Clark, T. A., et al. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-363 · Cited by 27
“In 2006 a major serogroup X epidemic caused by ST-181 affected the neighbouring country Niger [11,12] and the clone later spread to Burkina Faso [13].”
BackgroundInfluentialAn efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate
Fiebig, T., Romano, M. R., Oldrini, D., Adamo, R., Tontini, M., Brogioni, B., Santini, L., Berger, M., Costantino, P., Berti, F., et al. (2016) · npj Vaccines · doi:10.1038/npjvaccines.2016.17 · Cited by 27
Topaz, N., Caugant, D. A., Taha, M., Brynildsrud, O. B., Debech, N., Hong, E., Deghmane, A., Ouédraogo, R., Ousmane, S., Gamougame, K., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.054 · Cited by 27
Self-citationTunkel, A. R., van de Beek, D., & Scheld, W. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00084-9 · Cited by 27
Vaccine development against Neisseria meningitidis
Vogel, U. F., & Claus, H. (2010) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2010.00178.x · Cited by 28
“The next years will see the introduction of conjugated meningococcus A vaccines in Africa, of new conjugated tetravalent vaccines, and hopefully also of the first broadly cross-reactive MenB vaccines.”
BackgroundInfluentialTunkel, A. R., van de Beek, D., & Scheld, W. M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00089-8 · Cited by 27
Bennett, J. S., Bratcher, H. B., Brehony, C., Harrison, O. B., & Maiden, M. C. J. (2014) · Springer eBooks · doi:10.1007/978-3-642-30197-1_241 · Cited by 27
MenACWY-TT vaccine for active immunization against invasive meningococcal disease
Papaevangelou, V., & Spyridis, Ν. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.32 · Cited by 26
Knowledge, Attitudes, and Practices Related to Meningitis in Northern Ghana
Hayden, M. H., Dalaba, M. A., Awine, T., Akweongo, P., Nyaaba, G. N., Anaseba, D., Pelzman, J., Hodgson, A., & Pandya, R. E. (2013) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.12-0515 · Cited by 26
“affect the epidemiology of meningococcal disease and underscore the need for continued surveillance.(12,13)”
BackgroundCapsule switching of Neisseria meningitidis sequence type 7 serogroup A to serogroup X
Ji, X., Yao, P., Zhang, L.-Y., Li, Y., Xu, F., Mei, L., Zhu, S., Zhang, Y.-J., Zhu, H., & van der Veen, S. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.09.003 · Cited by 26
Sidikou, F., Cubeñas-Potts, C., Zaneidou, M., Mbaeyi, S. A., Kadadé, G., Paye, M. F., Ousmane, S., Issaka, B. B., Chen, A. J., Chang, H.-Y., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz296 · Cited by 26
“The CERMES has performed conventional (gel-based) polymerase chain reaction (PCR) to detect the 3 common bacterial meningitis pathogens (N meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae) and identify the 5 N meningitidis serogroups (A, B, C, W, and Y) since 2002 and implemented an assay to detect s…”
BackgroundMethodAdvances with vaccination against Neisseria meningitidis
Borrow, R. (2012) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2012.03085.x · Cited by 26
“Outbreaks of serogroup X have also been reported from the meningitis belt; for example, in Niger from January to June 2006, 51% of the 1139 confirmed cases of meningococcal meningitis were serogroup X (Boisier et al. 2007).”
BackgroundHedberg, S. T. (2009) · Cited by 26
Garrido, R., Puyada, A., Fernández, A., González, M., Ramírez, U., Cardoso, F., Valdés, Y., González, D., Fernández, V., Vérez-Bencomo, V. G., et al. (2012) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2012.07.014 · Cited by 25
Surveillance of Bacterial Meningitis, Ethiopia, 2012–2013
Mihret, W., Lema, T., Merid, Y., Kassu, A., Abebe, W., Moges, B., Tenna, A., Woldegebriel, F., Yidnekachew, M., Mekonnen, W., et al. (2015) · Emerging infectious diseases · doi:10.3201/eid2201.150432 · Cited by 25
“influenzae) for all samples, and capsule genogrouping was carried out for porA PCRpositive samples (7,8).”
BackgroundFraisier, C., Stor, R., Tenebray, B., Sanson, Y., & Nicolas, P. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02415-08 · Cited by 24
Self-citationChilukuri, S. R., Reddy, P. A., Avalaskar, N., Mallya, A. D., Pisal, S. S., & Dhere, R. M. (2014) · Biologicals · doi:10.1016/j.biologicals.2013.12.001 · Cited by 24
“In the recent past (2006e2010) there were outbreaks of MenX cases reported in Burkina Faso, Tago, Kenya and Ghana [1,2].”
BackgroundMeningococci of Serogroup X Clonal Complex 181 in Refugee Camps, Italy
Stefanelli, P., Neri, A., Vacca, P., Picicco, D., Daprai, L., Mainardi, G., Rossolini, G. M., Bartoloni, A., Anselmo, A., Ciammaruconi, A., et al. (2017) · Emerging infectious diseases · doi:10.3201/eid2305.161713 · Cited by 24
“Characteristics of MenX, CC181 genomes described in the analysis* ID (ID in http://pubmlst.org/ Neisseria) Country of origin (country of isolation) Year ST (CC) PorA VR1 PorA VR2 FetA fHbp NHBA lpt3 cgMLST group LNP13407 (34731) Chad 1995 ST181 (CC181) 5–1 10–1 F4–3 1.73 358 45 – LNP14354 (34732) Niger 1996 ST181 (CC1…”
BackgroundInfluentialThe changing face of meningococcal disease in West Africa
Greenwood, B. M. (2007) · Epidemiology and Infection · doi:10.1017/s0950268807008825 · Cited by 24
“In southwestern Niger meningococci belonging to this serogroup were responsible for 90% of cases [7].”
BackgroundAnalysis of the Bactericidal Response to an Experimental Neisseria meningitidis Vesicle Vaccine
Moran, E. E., Burden, R., Labrie, J. E., Wen, Z., Wang, X., Zollinger, W. D., Zhang, L., & Pinto, V. B. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00070-12 · Cited by 22
“While the strains assayed in this study have ST-5403, the majority of strains responsible for the serogroup X N. meningitidis epidemic and carriage in Africa have either ST-181 or ST-751 (3, 8, 21).”
BackgroundChanteau, S., Rose, A., Djibo, S., Nato, F., & Boisier, P. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.037 · Cited by 22
“Multiplex PCR is now in use for the ain virulent or epidemic-prone meningococcal serogroups , B, C, W135, X and Y [18,7], as well as for Streptococcus neumoniae [19] and Haemophilus influenzae b [20].”
BackgroundSelf-citationTechnical Development of a New Meningococcal Conjugate Vaccine
Frasch, C. E., Kapre, S. V., Lee, C., & Préaud, J.-M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ595 · Cited by 21
“groups X and W have caused small- and moderatesized outbreaks in Africa [2, 3].”
BackgroundMaïnassara, H. B., Paireau, J., Issa, I., Pelat, J.-P. M., Oukem‐Boyer, O. O. M., Fontanet, A. L., & Mueller, J. E. (2015) · Emerging infectious diseases · doi:10.3201/eid2108.141361 · Cited by 21
“Epidemic detection and response remains important because serogroups W and X have epidemic potential (1,2,4,8,9).”
BackgroundMethodLi, S., Liu, C., Liu, Y., Ma, Q., Wang, Y., & Wang, Y. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s210735 · Cited by 21
“meningitidis may vary geographically,(8) but serogroups A, B, C, W, X, and Y are responsible for the majority of the disease.(9,10,12) For example, serogroup B is the dominant serogroup of N.”
BackgroundSerogroup B meningococcal disease during Hajj: Preparing for the worst scenario
Khalil, M., & Borrow, R. (2009) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2009.07.001 · Cited by 21
“Carriage studies in Saudi Arabia showed that almost one third of the isolates were phenotypically nongroupable, not expressing a capsule, though genogrouping, by use of the capsular operon, of these has not, to date, been performed.13 Other serogroups may emerge, like serogroup B, for which no broad coverage vaccine i…”
BackgroundPajón, R., Fergus, A. M., & Granoff, D. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066536 · Cited by 20
“Widespread vaccination, however, could allow emergence of strains with other serogroups such as X (MenX) or W (MenW), which also cause epidemics in this region [13–15].”
BackgroundPaireau, J., Maïnassara, H. B., Jusot, J., Collard, J., Issa, I., Moulia-Pelat, J. P., Mueller, J. E., & Fontanet, A. L. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002899 · Cited by 20
“have also been reported [7–9].”
Rose, A., Gerstl, S., Mahamane, A. E.-H., Sidikou, F., Djibo, S., Bonte, L., Caugant, D. A., Guerin, P. J., & Chanteau, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007326 · Cited by 19
“[4–8] Different technicians performed culture and PCR, without knowledge of each other’s results, and one technician (author SC) performed all the repeat dipstick RDTs in one batch at the end of the study.”
MethodSelf-citationOkoko, B. J., Idoko, O. T., & Adegbola, R. A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.11.092 · Cited by 19
“[4] Boisier P, Nicolas S, Djibo M-K, Taha I, Jeanne HB, Maïnassara B, et al.”
BackgroundPajón, R., Lujan, E., & Granoff, D. M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.12.034 · Cited by 19
Acevedo, R., Zayas, C., Norheim, G., Fernández-Castillo, S., Cedré, B., Aranguren, Y., Cuello, M., Rodríguez, Y., González, H., Mandiarote, A., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.030 · Cited by 18
Control of meningococcal meningitis outbreaks in sub-Saharan Africa
Chippaux, J. (2008) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.193 · Cited by 18
“meningitidis A represented more than 85 % of the strains isolated in Niamey before the emergence of serogroups X and W135 [18] and serogroup A remains the predominant isolate even in countries where other serogroups have been responsible for large epidemics [19,20].”
BackgroundInfluentialA Multivalent Conjugate Vaccine for Prevention of Meningococcal Disease in Infants
Harrison, L. H. (2008) · JAMA · doi:10.1001/jama.2007.57-c · Cited by 18
Controlling serogroup B invasive meningococcal disease: the Canadian perspective
Bettinger, J. A., Deeks, S. L., Halperin, S. A., Tsang, R. S. W., & Scheifele, D. W. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.30 · Cited by 17
Bekkat-Berkani, R., Fragapane, E., Preiss, S., Rappuoli, R., Sohn, W.-Y., Soumahoro, L., & Vadivelu, K. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.09.001 · Cited by 17
Hama, M. K., Khan, D., Boubou, L., Okoi, C., Yam, A., Moussa, H., Worwui, A. K., Ndow, P. S., Obama, R., Mwenda, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz598 · Cited by 17
Field evaluation of rapid diagnostic tests for meningococcal meningitis in Niger
Boisier, P., Mahamane, A. E., Hamidou, A. A., Sidikou, F., Djibo, S., Nato, F., & Chanteau, S. (2008) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2008.02192.x · Cited by 17
Self-citationMeningococcal vaccines: a neglected topic in travel medicine?
Wilder‐Smith, A. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.102 · Cited by 16
Serogroup A meningococcal conjugate vaccines in Africa
Kristiansen, P. A., Jørgensen, H. J., & Caugant, D. A. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1084232 · Cited by 16
“Incidence peaked in 2011 during the first epidemic season after MenAfriVac introduction and the dominating clone was ST-181 [88], the same clone that had been responsible for outbreaks in Niger in 2006 [8] and was circulating among healthy Burkinabe carriers in 2009, 2010 and 2011 [81,88].”
BackgroundSerogroup W135 Meningococcal Meningitis, Northern Cameroon, 2007–2008
Massenet, D., Inrombe, J., Mevoula, D.-E., & Nicolas, P. (2009) · Emerging infectious diseases · doi:10.3201/eid1502.080988 · Cited by 16
Self-citationKarve, S. J., Misurski, D. A., Miller, J. M., & Davis, K. L. (2011) · Health Outcomes Research in Medicine · doi:10.1016/j.ehrm.2011.08.001 · Cited by 16
Leimkugel, J., Forgor, A. A., Dangy, J., Pflüger, V., Gagneux, S., Hodgson, A., & Pluschke, G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.035 · Cited by 15
Vicente, D. A., Esnal, O., & Pérez‐Trallero, E. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.11.009 · Cited by 15
Kuznik, A., Iliyasu, G., Lamorde, M., Mahmud, M., Musa, B. M., Nashabaru, İ., Obaro, S., Mohammed, I., & Habib, A. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188595 · Cited by 15
Micoli, F., Adamo, R., Proietti, D., Gavini, M., Romano, M. R., MacLennan, C. A., Costantino, P., & Berti, F. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.08.001 · Cited by 15
Neisseria meningitidisSerogroup X Sequence Type 2888, Italy
Fazio, C., Starnino, S., Soldà, M. D., Sofia, T., Neri, A., Mastrantonio, P., & Stefanelli, P. (2010) · Emerging infectious diseases · doi:10.3201/eid1602.091553 · Cited by 15
“meningitidis serogroup X represented 51% of confi rmed cases of meningitis (4).”
BackgroundEvaluation of response strategies against epidemics due to Neisseria meningitidis C in Niger
Maïnassara, H. B., Oumarou, G. I., Issaka, B. B., Sidiki, A., Issa, I., Pelat, J.-P. M., Fontanet, A. L., & Mueller, J. E. (2016) · Tropical Medicine & International Health · doi:10.1111/tmi.12815 · Cited by 14
Diallo, F., Haidara, F. C., Tapia, M. D., Islas, C. P. D., Alderson, M. R., Hausdorff, W. P., Martellet, L., Hosken, N. A., Kapse, D., Kulkarni, P. S., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00046-7 · Cited by 13
Tunheim, G., Næss, L. M., Acevedo, R., Fjeldheim, Å. K., Bolstad, K., Garcia, L. H. D. M. R., Cardoso, D., Aase, A., Zayas, C., González, H., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.09.063 · Cited by 13
Mobile Microbiological Laboratory Support for Evaluation of a Meningitis Epidemic in Northern Benin
Njanpop‐Lafourcade, B., Hugonnet, S., Djogbe, H., Kodjo, A., N’Douba, A. K., Taha, M., Stoeckel, P., & Gessner, B. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068401 · Cited by 13
Self-citationCharacteristics of Neisseria meningitidis isolates causing fatal disease
Jacobsson, S., Olcén, P., Löfdahl, M., Fredlund, H., & Mölling, P. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540802029565 · Cited by 13
“Serogroup A, B, C, Y and W-135 are most commonly associated with Mcd, where serogroup A, B and C isolates are responsible for about 90% of the cases [1] and serogroup W-135, Y and occasionally X have emerged in the past 10 y [11].”
BackgroundThe Development of an Experimental Multiple Serogroups Vaccine for Neisseria meningitidis
Pinto, V. B., Burden, R., Wagner, A., Moran, E. E., & Lee, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079304 · Cited by 12
Development and Evaluation of a Dipstick Diagnostic Test for Neisseria meningitidis Serogroup X
Agnememel, A., Traincard, F., Dartevelle, S., Mulard, L. A., Mahamane, A. E., Oukem‐Boyer, O. O. M., Denizon, M., Kacou-N'douba, A., Dosso, M. B., Gaké, B., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02444-14 · Cited by 12
“This unique NmX-specific test could be added to the available set of RDT for the detection of meningococcal meningitis in Africa as a major tool to reinforce epidemiological surveillance after the introduction of the NmA conjugate vaccine.”
BackgroundSelf-citationSynthesis of Neisseria meningitidis X capsular polysaccharide fragments
Morelli, L., & Lay, L. (2012) · ARKIVOC · doi:10.3998/ark.5550190.0014.214 · Cited by 12
Gorla, M. C., Brandão, A. P., Pinhata, J. M. W., de Moraes, C., Pereira, G. M., & de Lemos, A. P. S. (2019) · Access Microbiology · doi:10.1099/acmi.0.000079 · Cited by 12
Tønjum, T., & van Putten, J. P. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00179-9 · Cited by 13
Deghmane, A., Haeghebaert, S., Hong, E., Jousset, A., Barret, A., & Taha, M. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.01.020 · Cited by 11
“Vaccine 2016; 34 (March (13)):1515–23 PubMed PMID:26876439.”
Self-citationControl of invasive meningococcal disease: is it achievable?
Marshall, H. S., Wang, B., Wesselingh, S. L., Snape, M. D., & Pollard, A. J. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000048 · Cited by 11
“Capsular group X is rare and tends to cause sporadic outbreaks, the majority of which occur in Africa.27 Prior to the implementation of the national capsular group C meningococcal (MenC) immunization programme in the United Kingdom (November 1999) and in Australia (January 2003), one-third of the cases in both the cou…”
BackgroundMolecular Characterization of Invasive Isolates of Neisseria meningitidis in Casablanca, Morocco
Razki, A., Hong, E., Zerouali, K., Belabbès, H., Aitmouss, K., Terrade, A., Zaki, B., Deghmane, A., Elmdaghri, N., & Taha, M. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00445-18 · Cited by 11
Self-citationBa, A. K., Sanou, I., Kristiansen, P. A., Lassana, S., Ouédraogo, R., Ouattara, K., Kienou, M., Tiendrébéogo, S., & Tranchot‐Diallo, J. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0546-8 · Cited by 11
“Because countries neighboring Burkina Faso such as Niger and Ghana have recently experienced the circulation and epidemic outbreak of serogroup X meningitis [23,27], the presence in our study of NmX is alarming as new serogroups with epidemic potential could replace or be added to serogroup A.”
BackgroundMolecular epidemiology of infectious diseases: the example of meningococcal disease
Taha, M., & Alonso, J. (2007) · Research in Microbiology · doi:10.1016/j.resmic.2007.11.017 · Cited by 10
Self-citationPollard, A. J., & Finn, A. H. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00127-6 · Cited by 10
Arifin, S. M. N., Zimmer, C., Trotter, C. L., Colombini, A., Sidikou, F., LaForce, F. M., Cohen, T., & Yaesoubi, R. (2019) · Medical Decision Making · doi:10.1177/0272989x19859899 · Cited by 9
Epidemiological Patterns of Bacterial Meningitis in Niger from 2002 to 2010
Maïnassara, H. B., Sidikou, F., Djibo, S., Soussou, A. M., Issaka, B. B., Sidiki, A., & Rocourt, J. (2014) · Science Journal of Public Health · doi:10.11648/j.sjph.20140202.13 · Cited by 9
“A significant increase in the incidence of serogroup X, for which a vaccine is not yet available, was also observed in 2006 [11] in Niger.”
BackgroundResultInfluentialSelf-citationThe new first-line defense: the potential of nasopharyngeal colonization in vaccine strategies
Chan, W.-Y., Cohen, J., & Brown, J. (2016) · Vaccine Development and Therapy · doi:10.2147/vdt.s89026 · Cited by 9
“In addition, serogroup X has more recently been identified as the cause of sepsis and meningitis in Africa.(52) Group A causes large-scale epidemics mainly in Africa but also in Asia, whereas the majority of cases of N.”
Meningococcal Vaccines: To Eradicate the Disease, not the Bacterium
Taha, M., & Alonso, J. (2007) · Human Vaccines · doi:10.4161/hv.3.4.4174 · Cited by 9
Self-citationNovel assessment of a novel meningitis B vaccine
Gill, C. J. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70037-9 · Cited by 9
Neisseria meningitidisSerogroup X ST-5799 (ST-22 complex) in Turkey: A unique pediatric case
Tanır, G., Özsürekçi, Y., Lucidarme, J., Durmuş, S. Y., Lekshmi, A., Akısoglu, Ö. A., Aycan, A. E., Borrow, R., & Ceyhan, M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1377380 · Cited by 8
“The most isolated clone was also ST-181 in this study.(4) Therefore,”
BackgroundReyes, F., Otero, O., Camacho, F., Amín, N., Bencomo, F. R., Valdés, Y., Acevedo, R., García, L. G., Cardoso, D., & Cuello, M. (2014) · Biologicals · doi:10.1016/j.biologicals.2014.08.001 · Cited by 8
Rouphael, N., Zimmer, S. M., & Stephens, D. S. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369408-9.00053-6 · Cited by 8
Katz, S. E., Townsend‐Payne, K., Louth, J. C., Lee‐Jones, L., Trotter, C. L., Dano, I. D., & Borrow, R. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.013 · Cited by 7
A vaccine to prevent epidemic meningitis in Africa
Greenwood, B. M., & Stuart, J. M. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70182-2 · Cited by 7
Bettencourt, C. R., Nunes, A., Correia, A. M., Gomes, J. P., & Simões, M. J. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03977-7 · Cited by 7
Bacterial meningitis in Niger: an analysis of national surveillance data, 2003-2015
Manzo, L. M., Ousmane, S., Dano, I. D., Zaneidou, M., Testa, J., & Maïnassara, H. B. (2018) · Pan African Medical Journal · doi:10.11604/pamj.2018.30.235.15937 · Cited by 7
Basu, N., Mukherjee, M., & Ghosh, R. (2025) · Carbohydrate Research · doi:10.1016/j.carres.2025.109545 · Cited by 6
Kale, S., Phugare, S., Sharma, P. L., Goel, S. K., & Gairola, S. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115679 · Cited by 6
Meningococcal Meningitis: Etiology, Diagnosis, Epidemiology and Treatment
Ahmed-Abakur, E. H. (2014) · American Journal of Medicine and Medical Sciences · Cited by 6
Page, A., Coldiron, M. E., Gamougam, K., Acyl, M. A., Tamadji, M., Lastrucci, C., Hurtado, N., Tehoua, F., Fermon, F., Caugant, D. A., et al. (2017) · Tropical Medicine & International Health · doi:10.1111/tmi.12987 · Cited by 6
“Historically, the largest outbreaks of meningitis have been caused by Neisseria meningitidis serogroup A (NmA), but serogroups C [3], X [4, 5] and W [6] have also caused outbreaks.”
BackgroundPhugare, S., Kale, S., Sharma, P. L., Goel, S. K., Gairola, S., & Jadhav, S. S. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.10.017 · Cited by 6
Medhane, M., Tunheim, G., Næss, L. M., Mihret, W., Bedru, A., Norheim, G., Petros, B., Aseffa, A., & Rosenqvist, E. (2014) · Scandinavian Journal of Immunology · doi:10.1111/sji.12150 · Cited by 6
Pollard, A. J., & Finn, A. H. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40181-4.00125-0 · Cited by 6
Anderson, M. S., Glodé, M. P., & Smith, A. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50104-7 · Cited by 6
Genomic characterization of invasive meningococcal X isolates from Brazil, 1992–2022
Cassiolato, A. P., Camargo, C. H., Cecconi, M. C., Christakis, S., Gonçalves, C. R., Campos, K. R., Higa, F. T., Pereira, G. A., de Moraes, C., & de Lemos, A. P. S. (2023) · International Microbiology · doi:10.1007/s10123-023-00325-5 · Cited by 5
“, 2017), outbreaks and huge epidemics are reported from Burkina Faso, Ghana, Kenya, Niger, and Togo from 1990 until recently (Gagneux et al., 2002; Boisier et al., 2007; Mutonga et al., 2009; Delrieu et al., 2011).”
BackgroundAnalytical Challenges in Novel Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W, X)
Sharma, P. L., Kale, S., Phugare, S., Goel, S. K., & Gairola, S. (2024) · Vaccines · doi:10.3390/vaccines12111227 · Cited by 5
Rinaldi, F. M. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.87.2014.tde-08122014-092828 · Cited by 5
Maïnassara, H. B., Paireau, J., Issa, I., Jusot, J., Pelat, J.-P. M., Oukem‐Boyer, O. O. M., Fontanet, A. L., & Mueller, J. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163110 · Cited by 4
“[3], the ST-181 clonal complex, responsible of all epidemic NmX events inWest Africa since 2005–06, may be more virulent than other clonal complexes, despite its genetic proximity with ST-751.”
Background
Metadata
- Authors
- Boisier, P., Nicolas, P., Djibo, S., Taha, M.-K., Jeanne, I., Mainassara, H. B., Tenebray, B., Kairo, K. K., Giorgini, D., & Chanteau, S.
- Affiliations
- Centre de Recherche Médicale et Sanitaire (NE)
- World Health Organization (CH)
- Institut Pasteur (FR)
- Ministère de la Santé Publique (NE)
- Corresponding author
- Boisier, P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-01
- Volume
- 44
- Issue
- 5
- Pages
- 657-663
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2159099211
- Cited by
- 237
- References
- 26
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 12 · 2017: 12 · 2016: 15 · 2015: 14 · 2014: 21 · 2013: 23 · 2012: 34
- FWCI
- 16.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- World Health Organization
- Wellcome Trust
- University of Oxford
- European Commission
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- meningococcal meningitis, serogroup W135, epidemic meningitis, meningitis incidence, Niger, Niamey, serogroup replacement, children aged 5-9 years
- MeSH terms
- Disease Outbreaks, Humans, Meningitis, Meningococcal, Neisseria meningitidis, Niger, Serotyping, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.